New Data Shows Canadians Are Informed About Fertility Ahead of Awareness Week
Ahead of Fertility Awareness Week, four top Canadian fertility clinics reveal new data proving Canadians are more informed than ever on family planning.
TORONTO, April 07, 2025--(BUSINESS WIRE)--As Fertility Awareness Week approaches, new data from four leading fertility clinics across the country, Generation Fertility, Grace Fertility, Heartland Fertility, and Ottawa Fertility Centre, reveals that Canadians are increasingly informed about fertility realities. The survey, conducted among members of the Angus Reid Forum, suggests that awareness campaigns are driving positive action, dispelling long-standing myths around reproductive health.
Infertility impacts one in six Canadians1, and these findings key insights into conception, gender, and age to empower Canadians to make informed family-planning decisions.
Key Findings
Canadians Have Realistic Grasp of Conception Timelines - More than half (54%) of Canadians correctly expect conception to take up to six months, and the majority (83%) anticipate pregnancy within a year.
Canadian perception is in line with global scientific findings, showing cumulative conception rates of approximately 75% after six months2.
Fertility Not Just a Women's Issue – Encouragingly, 65% of Canadians recognize that fertility challenges affect both men and women equally.
This data aligns with global fertility research, indicating that infertility is equally attributed to male factors, female factors, and unexplained causes in one-third of couples.
The Fertility Wake-Up Call: 40 is Not the New 30 - Nearly half (48%) of Canadians believe people should start thinking about family planning between 25-30, with men (25%) more likely than women (18%) to believe fertility awareness should begin even earlier.
Consistent with global data, this finding shows women's fertility does decline gradually but significantly starting around age 32, with a more rapid decrease after age 37.
"Canadians are more informed than ever before about fertility, and while we've come a long way, there is still progress to be made," says Dr. Michael Hartman, Fertility Specialist and Medical Director at Generation Fertility. "While general guidelines suggest trying for six months to a year depending on age, we at Generation Fertility suggest that Canadians seek help sooner rather than later because time is crucial if a problem exists."
Provincial Highlights: Regional Awareness Trends
Ontarians Recognize the Realities of Conception
Over half (51%) of Canadians expect conception to occur within the first six months of trying, and 82% expect it will take up to a year. While many Ontarians still anticipate being able to get pregnant relatively quickly, awareness efforts are helping Canadians understand the reality.
"Over our 30 years of providing fertility care and research in Canada, we have seen progress in fertility awareness regarding conception times - these statistics reflect that. It is encouraging to see some patients seeking care earlier, but there is still progress to be made here. Not only does earlier access to care allow for better counselling around options and time to consider these options, but it improves the chance of success with either fertility preservation or fertility treatments to optimize the ability to achieve a person's overall family building goals," says Dr. Jenna Gale, Fertility Specialist at Ottawa Fertility Centre.
British Columbians Acknowledge Male Fertility Factors
In British Columbia., 62% of residents correctly recognize that infertility is not gender-specific. While gaps in knowledge persist, 38% still primarily attribute fertility challenges to women, and this awareness marks a positive shift in understanding the role of male fertility.
"The age-old myth that women bear most of the responsibility for infertility is false. It is key for both partners to undergo fertility assessments to ensure they are addressing all potential factors affecting conception, rather than focusing on one partner's perceived responsibility." - Dr. Ghadeer Akbar, Fertility Specialist at Grace Fertility. "That being said, as women age, egg quality naturally declines. It's never too early to consider egg freezing to preserve your fertility.
Manitobans Are Prioritizing Early Family Planning
Notably, 41% of Manitobans believe in considering family planning between ages 25-30, indicating a proactive approach to fertility, ensuring timely assessments and informed decision-making.
"As a fertility specialist, I've seen Canadians become more aware that pregnancy takes time, especially as women age. Despite greater awareness of fertility challenges, women often bear the weight of guilt and self-blame. I hope greater fertility awareness helps people see that they are not alone, and that it's not their fault," says Dr. Stephanie Appleby, Fertility Specialist at Heartland Fertility. "If you suspect reproductive issues, see a specialist. It's never too soon to take control of your fertility."
Awareness in Action
These findings confirm that national fertility awareness efforts are shifting public perception in a meaningful way. While there is still work to be done, the data demonstrates that Canadians are increasingly well-informed, making educated decisions about their reproductive health.
Methodology:
These are the findings of a study/survey conducted by four clinics within The Fertility Partners network including Generation Fertility, Grace Fertility, Ottawa Fertility Centre, and Heartland Fertility from March 3rd to 4th, 2025 among a representative sample of 1,563 online Canadians who are members of the Angus Reid Forum. The survey was conducted in English and French. For comparison purposes only, a probability sample of this size would carry a margin of error of +/- 2.5 percentage points, 19 times out of 20.
1 WHO
2 National Library of Medicine
View source version on businesswire.com: https://www.businesswire.com/news/home/20250407721097/en/
Contacts
MEDIA Lindsay Silverberglindsay@chimera-collective.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
3 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
11 hours ago
- Yahoo
AIDS 5K Walk/Run cancelled due to wildfire smoke
LIVERPOOL, N.Y. (WSYR-TV) — The Canadian wildfire smoke in Central New York has caused the AIDS 5K Walk/Run to be cancelled. The run was originally scheduled for Sunday, June 8, 2025 at Onondaga Lake Park in Liverpool at the Saw Mill Creek Shelter. The decision to cancel the event was made because the air quality at this level can affect sensitive groups and others, especially during physical activity. The Air Quality Alert for Central New York will last until Sunday, 11:59 June 8. Organizers will share more information in the coming days. If anyone who has already registered for the event wishes to request a refund, they can contact klowe@ Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.